A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma.

MLA

Ghobadi, Armin, et al. “A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma.” Clinical Lymphoma, Myeloma & Leukemia, vol. 19, no. 10, Oct. 2019, pp. e588–93. EBSCOhost, https://doi.org/10.1016/j.clml.2019.04.017.

APA

Ghobadi, A., Fiala, M. A., Rettig, M., Schroeder, M., Uy, G. L., Stockerl-Goldstein, K., Westervelt, P., Vij, R., & DiPersio, J. F. (2019). A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma. Clinical Lymphoma, Myeloma & Leukemia, 19(10), e588–e593. https://doi.org/10.1016/j.clml.2019.04.017

Chicago

Ghobadi, Armin, Mark A Fiala, Michael Rettig, Mark Schroeder, Geoffrey L Uy, Keith Stockerl-Goldstein, Peter Westervelt, Ravi Vij, and John F DiPersio. 2019. “A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma.” Clinical Lymphoma, Myeloma & Leukemia 19 (10): e588–93. doi:10.1016/j.clml.2019.04.017.